Regulus Therapeutics IncNASDAQ RGLS Stock Report

Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. The company is headquartered in San Diego, California and currently employs 27 full-time employees. The company went IPO on 2012-10-04. The firm is leveraging its oligonucleotide drug discovery and development to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. The Company’s product lead product candidates include RG-012 and RGLS8429. The firm is focused on evaluating a library of oligonucleotides designed to block miR-155 for the potential to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease). The firm also focuses on the evaluation of its designed compounds that inhibit miR-155 activity in microglia cell-based assays and in animal models of the disease, to identify potential candidates to advance into further studies. In addition to its focus on genetic kidney disease, the Company is focused on the research in technology to treat central nervous system (CNS) disease.